Search Results - "Jenkins, Russell"

Mechanisms of resistance to immune checkpoint inhibitors by Jenkins, Russell W, Barbie, David A, Flaherty, Keith T

“…Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have shown unprecedented clinical activity in several types of cancer and are…”
Get full text

Treatment of Advanced Melanoma in 2020 and Beyond by Jenkins, Russell W., Fisher, David E.

“…The melanoma field has seen an unprecedented set of clinical advances over the past decade. Therapeutic efficacy for advanced or metastatic melanoma went from…”
Get full text

Mechanisms of Resistance to Immune Checkpoint Blockade by Liu, David, Jenkins, Russell W., Sullivan, Ryan J.

“…The recent development of effective immune checkpoint inhibition (ICI), first demonstrated in melanoma, has revolutionized cancer treatment. Monoclonal…”
Get full text

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade by Jerby-Arnon, Livnat, Shah, Parin, Cuoco, Michael S., Rodman, Christopher, Su, Mei-Ju, Melms, Johannes C., Leeson, Rachel, Kanodia, Abhay, Mei, Shaolin, Lin, Jia-Ren, Wang, Shu, Rabasha, Bokang, Liu, David, Zhang, Gao, Margolais, Claire, Ashenberg, Orr, Ott, Patrick A., Buchbinder, Elizabeth I., Haq, Rizwan, Hodi, F. Stephen, Boland, Genevieve M., Sullivan, Ryan J., Frederick, Dennie T., Miao, Benchun, Moll, Tabea, Flaherty, Keith T., Herlyn, Meenhard, Jenkins, Russell W., Thummalapalli, Rohit, Kowalczyk, Monika S., Cañadas, Israel, Schilling, Bastian, Cartwright, Adam N.R., Luoma, Adrienne M., Malu, Shruti, Hwu, Patrick, Bernatchez, Chantale, Forget, Marie-Andrée, Barbie, David A., Shalek, Alex K., Tirosh, Itay, Sorger, Peter K., Wucherpfennig, Kai, Van Allen, Eliezer M., Schadendorf, Dirk, Johnson, Bruce E., Rotem, Asaf, Rozenblatt-Rosen, Orit, Garraway, Levi A., Yoon, Charles H., Izar, Benjamin, Regev, Aviv

“…Immune checkpoint inhibitors (ICIs) produce durable responses in some melanoma patients, but many patients derive no clinical benefit, and the molecular…”
Get full text

Targeting TANK-binding kinase 1 (TBK1) in cancer by Revach, Or-Yam, Liu, Shuming, Jenkins, Russell W

“…TANK-binding kinase 1 (TBK1) is a Ser/Thr kinase with a central role in coordinating the cellular response to invading pathogens and regulating key…”
Get more information

Mapping the immune environment in clear cell renal carcinoma by single-cell genomics by Borcherding, Nicholas, Vishwakarma, Ajaykumar, Voigt, Andrew P., Bellizzi, Andrew, Kaplan, Jacob, Nepple, Kenneth, Salem, Aliasger K., Jenkins, Russell W., Zakharia, Yousef, Zhang, Weizhou

“…Clear cell renal cell carcinoma (ccRCC) is one of the most immunologically distinct tumor types due to high response rate to immunotherapies, despite low tumor…”
Get full text

3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade by Aref, Amir R, Campisi, Marco, Ivanova, Elena, Portell, Andrew, Larios, Dalia, Piel, Brandon P, Mathur, Natasha, Zhou, Chensheng, Coakley, Raven Vlahos, Bartels, Alan, Bowden, Michaela, Herbert, Zach, Hill, Sarah, Gilhooley, Sean, Carter, Jacob, Cañadas, Israel, Thai, Tran C, Kitajima, Shunsuke, Chiono, Valeria, Paweletz, Cloud P, Barbie, David A, Kamm, Roger D, Jenkins, Russell W

“…Microfluidic culture has the potential to revolutionize cancer diagnosis and therapy. Indeed, several microdevices are being developed specifically for…”
Get more information

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma by Sade-Feldman, Moshe, Yizhak, Keren, Bjorgaard, Stacey L., Ray, John P., de Boer, Carl G., Jenkins, Russell W., Lieb, David J., Chen, Jonathan H., Frederick, Dennie T., Barzily-Rokni, Michal, Freeman, Samuel S., Reuben, Alexandre, Hoover, Paul J., Villani, Alexandra-Chloé, Ivanova, Elena, Portell, Andrew, Lizotte, Patrick H., Aref, Amir R., Eliane, Jean-Pierre, Hammond, Marc R., Vitzthum, Hans, Blackmon, Shauna M., Li, Bo, Gopalakrishnan, Vancheswaran, Reddy, Sangeetha M., Cooper, Zachary A., Paweletz, Cloud P., Barbie, David A., Stemmer-Rachamimov, Anat, Flaherty, Keith T., Wargo, Jennifer A., Boland, Genevieve M., Sullivan, Ryan J., Getz, Gad, Hacohen, Nir

“…Treatment of cancer has been revolutionized by immune checkpoint blockade therapies. Despite the high rate of response in advanced melanoma, the majority of…”
Get full text

Roles and regulation of secretory and lysosomal acid sphingomyelinase by Jenkins, Russell W., Canals, Daniel, Hannun, Yusuf A.

“…Acid sphingomyelinase occupies a prominent position in sphingolipid catabolism, catalyzing the hydrolysis of sphingomyelin to ceramide and phosphorylcholine…”
Get full text

Anticancer actions of lysosomally targeted inhibitor, LCL521, of acid ceramidase by Bai, Aiping, Mao, Cungui, Jenkins, Russell W, Szulc, Zdzislaw M, Bielawska, Alicja, Hannun, Yusuf A

“…Acid ceramidase, which catalyzes ceramide hydrolysis to sphingosine and free fatty acid mainly in the lysosome, is being recognized as a potential therapeutic…”
Get full text

Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases by Canals, Daniel, Perry, David M, Jenkins, Russell W, Hannun, Yusuf A

“…Sphingolipids represent a class of diverse bioactive lipid molecules that are increasingly appreciated as key modulators of diverse physiologic and…”
Get full text

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation by Deng, Jiehui, Wang, Eric S, Jenkins, Russell W, Li, Shuai, Dries, Ruben, Yates, Kathleen, Chhabra, Sandeep, Huang, Wei, Liu, Hongye, Aref, Amir R, Ivanova, Elena, Paweletz, Cloud P, Bowden, Michaela, Zhou, Chensheng W, Herter-Sprie, Grit S, Sorrentino, Jessica A, Bisi, John E, Lizotte, Patrick H, Merlino, Ashley A, Quinn, Max M, Bufe, Lauren E, Yang, Annan, Zhang, Yanxi, Zhang, Hua, Gao, Peng, Chen, Ting, Cavanaugh, Megan E, Rode, Amanda J, Haines, Eric, Roberts, Patrick J, Strum, Jay C, Richards, William G, Lorch, Jochen H, Parangi, Sareh, Gunda, Viswanath, Boland, Genevieve M, Bueno, Raphael, Palakurthi, Sangeetha, Freeman, Gordon J, Ritz, Jerome, Haining, W Nicholas, Sharpless, Norman E, Arthanari, Haribabu, Shapiro, Geoffrey I, Barbie, David A, Gray, Nathanael S, Wong, Kwok-Kin

“…Immune checkpoint blockade, exemplified by antibodies targeting the PD-1 receptor, can induce durable tumor regressions in some patients. To enhance the…”
Get more information

Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer by Jenkins, Russell W, Thummalapalli, Rohit, Carter, Jacob, Cañadas, Israel, Barbie, David A

“…Molecularly targeted therapy and immunotherapy have dramatically changed the landscape of available treatment options for patients with advanced cancer…”
Get full text

Going with the Flow: Modeling the Tumor Microenvironment Using Microfluidic Technology by Xie, Hongyan, Appelt, Jackson W., Jenkins, Russell W.

“…Recent advances in cancer immunotherapy have led a paradigm shift in the treatment of multiple malignancies with renewed focus on the host immune system and…”
Get full text

Mutant IDH Inhibits IFNγ-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma by Wu, Meng-Ju, Shi, Lei, Dubrot, Juan, Merritt, Joshua, Vijay, Vindhya, Wei, Ting-Yu, Kessler, Emily, Olander, Kira E, Adil, Ramzi, Pankaj, Amaya, Tummala, Krishna Seshu, Weeresekara, Vajira, Zhen, Yuanli, Wu, Qibiao, Luo, Meiqi, Shen, William, García-Beccaria, María, Fernández-Vaquero, Mirian, Hudson, Christine, Ronseaux, Sebastien, Sun, Yi, Saad-Berreta, Rodrigo, Jenkins, Russell W, Wang, Tong, Heikenwälder, Mathias, Ferrone, Cristina R, Goyal, Lipika, Nicolay, Brandon, Deshpande, Vikram, Kohli, Rahul M, Zheng, Hongwu, Manguso, Robert T, Bardeesy, Nabeel

“…Isocitrate dehydrogenase 1 mutations (mIDH1) are common in cholangiocarcinoma. (R)-2-hydroxyglutarate generated by the mIDH1 enzyme inhibits multiple…”
Get more information

Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway by Zeidan, Youssef H, Jenkins, Russell W, Hannun, Yusuf A

“…The chemotherapeutic agent cisplatin is widely used in treatment of solid tumors. In breast cancer cells, cisplatin produces early and marked changes in cell…”
Get full text

Targeting TBK1 to overcome resistance to cancer immunotherapy by Sun, Yi, Revach, Or-yam, Anderson, Seth, Kessler, Emily A., Wolfe, Clara H., Jenney, Anne, Mills, Caitlin E., Robitschek, Emily J., Davis, Thomas G. R., Kim, Sarah, Fu, Amina, Ma, Xiang, Gwee, Jia, Tiwari, Payal, Du, Peter P., Sindurakar, Princy, Tian, Jun, Mehta, Arnav, Schneider, Alexis M., Yizhak, Keren, Sade-Feldman, Moshe, LaSalle, Thomas, Sharova, Tatyana, Xie, Hongyan, Liu, Shuming, Michaud, William A., Saad-Beretta, Rodrigo, Yates, Kathleen B., Iracheta-Vellve, Arvin, Spetz, Johan K. E., Qin, Xingping, Sarosiek, Kristopher A., Zhang, Gao, Kim, Jong Wook, Su, Mack Y., Cicerchia, Angelina M., Rasmussen, Martin Q., Klempner, Samuel J., Juric, Dejan, Pai, Sara I., Miller, David M., Giobbie-Hurder, Anita, Chen, Jonathan H., Pelka, Karin, Frederick, Dennie T., Stinson, Susanna, Ivanova, Elena, Aref, Amir R., Paweletz, Cloud P., Barbie, David A., Sen, Debattama R., Fisher, David E., Corcoran, Ryan B., Hacohen, Nir, Sorger, Peter K., Flaherty, Keith T., Boland, Genevieve M., Manguso, Robert T., Jenkins, Russell W.

“…Despite the success of PD-1 blockade in melanoma and other cancers, effective treatment strategies to overcome resistance to cancer immunotherapy are lacking 1…”
Get full text

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma by Sade-Feldman, Moshe, Yizhak, Keren, Bjorgaard, Stacey L., Ray, John P., de Boer, Carl G., Jenkins, Russell W., Lieb, David J., Chen, Jonathan H., Frederick, Dennie T., Barzily-Rokni, Michal, Freeman, Samuel S., Reuben, Alexandre, Hoover, Paul J., Villani, Alexandra-Chloé, Ivanova, Elena, Portell, Andrew, Lizotte, Patrick H., Aref, Amir R., Eliane, Jean-Pierre, Hammond, Marc R., Vitzthum, Hans, Blackmon, Shauna M., Li, Bo, Gopalakrishnan, Vancheswaran, Reddy, Sangeetha M., Cooper, Zachary A., Paweletz, Cloud P., Barbie, David A., Stemmer-Rachamimov, Anat, Flaherty, Keith T., Wargo, Jennifer A., Boland, Genevieve M., Sullivan, Ryan J., Getz, Gad, Hacohen, Nir

Get full text

Emerging roles of TBK1 in cancer immunobiology by Miranda, Alex, Shirley, Carl A, Jenkins, Russell W

“…TANK-binding kinase 1 (TBK1) is a versatile serine/threonine protein kinase with established roles in innate immunity, metabolism, autophagy, cell death, and…”
Get more information

Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting by Ventin, Marco, Cattaneo, Giulia, Arya, Shahrzad, Jia, Jingyu, Gelmi, Maria C, Sun, Yi, Maggs, Luke, Ksander, Bruce R, Verdijk, Robert M, Boland, Genevieve M, Jenkins, Russell W, Haq, Rizwan, Jager, Martine J, Wang, Xinhui, Ryeom, Sandra, Ferrone, Cristina R

“…Uveal melanoma (UM) is the most common intraocular malignant tumor. Despite successful treatment of the primary tumor, about 50% of patients will recur with…”
Get full text